Dietetic composition for decreasing body weight gain and method for decreasing body weight gain

FIELD: food additives.

SUBSTANCE: it has been developed both the dietetic composition and method in which one should apply the foundation as food for mammalians and an active component being an estrogen, androgen or their mixture at the quantity to be sufficient for preventing body weight gain usually happened in mammalians after delayed maturation of reproductive organs, castration, ovariectomy or hysterectomy, or during post-climacteric period. Preferably, active component is being a phytoestrogen, phytoandrogen or their mixture, at the quantity 0.001-10 weight% against the weight of composition. Application of compositions efficiently prevents body weight gain in mammalians.

EFFECT: higher efficiency.

4 ex, 3 tbl

 

The technical field to which the invention relates.

The present invention relates to the field of food additives, in particular to the diet compositions, mainly intended for mammals, including humans, dogs, cats and horses, as well as to a method of reducing weight gain usually occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period.

The level of technology

Methods, including sterilization, castration, oophorectomy or ovariohysterectomy increasingly used on dogs and cats for reasons relating to their health and/or the regulation of their numbers. After the dogs or cats are one of these impacts, there is a significant increase (set) of their weight, which often goes beyond the typical for healthy object.

Increase (set) of body weight after removal of the ovaries, oophorectomy or ovariohysterectomy often observed in other mammals, including humans. In addition, postclimacteric weight gain often seen in people even when not held oophorectomy or ovariohysterectomy.

Despite the fact that currently available systems and methods reduce weight and prevent the possible weight gain, typically, such systems and methods are difficult to implement on a continuous basis and/or they are ineffective for a long time. Thus, there is a need for improved systems for reducing weight gain usually occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period.

The invention

The purpose of the present invention is to develop a diet compositions and methods that are superior to known analogs. A more specific object of the invention is to create a diet compositions and methods, particularly intended for mammals, which provide reduction of weight gain usually occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period. Another objective of the present invention is to provide compositions and methods that can easily be used on humans and other mammals, including dogs, cats and horses.

These and other objectives and advantages are provided by a diet compositions and methods of the present invention. Diet composition of the present invention are particularly suitable for consumption by mammals which include food-based and component containing estrogen, androgen, or their mixture in a quantity sufficient to reduce the weight gain that typically occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period when daily or other regular use of diet composition. According to a preferred technical solution, these components include phytoestrogen, fitoestrogen or their mixture. The methods of the present invention is aimed at reducing weight gain, usually occurring in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period. Such methods include daily or other regular use of mammal diet composition, including food base and the component containing the estrogen, androgen, or their mixture in a quantity sufficient to reduce the weight gain that typically occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or in the postmenopausal period, and such a composition is applied on a daily or other regular way. In accordance with preferred embodiments of such methods, the specified component contains phytoestrogen, fitoestrogen is whether their mixture.

Other objectives and advantages provided by the compositions and methods of the present invention will become clearer from the following detailed description of the invention.

Diet composition of the present invention are suitable for consumption by mammals and are designed to reduce weight gain usually occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period, especially when the diet composition is applied daily or other regular way. Consider the composition include food-based and component, including estrogen, androgen, and their mixture. Estrogen and androgen suitable for use in compositions and methods according to the invention, can be obtained from natural or synthetic source, having, respectively, estrogenic or androgenic activity.

According to a preferred variant embodiment of the present invention using a phytoestrogen, fitoestrogen or their mixture. Phytoestrogen and fitoestrogen preferred for use in compositions according to the invention can be obtained from various plants. Preferred vegetable sources phytoestrogen include soybean or isolated from it prod the points, for example purified soy protein or soy hypocotyl, and flax seed or a selection of it products such as purified linseed protein, although you can use other plants such as red clover and other species of clover, alfalfa, alfalfa tabuloconida, chick peas, lentils, beans, Chinese rose and/or grapes. In addition to these sources of phytoestrogen, fitoestrogeny can be found in such sources as Serenoa repens, Dalbergia cochinchinensis, Brosimum rubescens, parasitic weed, striga orobanchioides and Azadurachta indica. The examples are merely illustrative and do not represent an exhaustive list. The specialist in this area should be clear that in diet compositions and/or methods of the present invention can be used and other sources of phytoestrogen and/or fitoestrogeni. In the most preferred embodiments use phytoestrogen and/or phytoestrogens derived from soy and Flaxseed. Examples of specific groups phytoestrogenic compounds for use in compositions according to the invention include, but are not limited to, isoflavones, lignans, kometani, lactones resorcinol acid and mixtures thereof. Especially preferred sources of phytoestrogens for diet compositions according to the invention are daidzein, genistein and coumestrol. Others who issued the preferred sources are formononetin, genistin, daidzin, ononin, sistren, resveratrol and biochanin a Specialist in this area should be clear that during fermentation glycosides such as daidzin, genistin become aglionby connection, daidzein and genistein.

In accordance with an alternative variant embodiment, the estrogen and androgen may be derived from fungal, microbial and other natural sources, having estrogenic or androgenic activity, respectively, or such components may be produced synthetically using known methods. In this regard, a preferred example of obtaining components of synthetic origin can serve as enzymatic conversion isoflavonones of glycoside in aglionby form.

Food base, which is added to estrogen and/or androgen, may be any suitable food component, including, but not limited to, food of animal origin, such as meat or dairy products, or substances of plant origin, including such cereals like oats or bran, starch, mono-, di-, poly - or oligosaccharides, pomace flour, other cellulosic materials, or mixtures thereof. The choice of a particular food base for the compositions of the present invention will in part depend on the desired type of the final diets the political composition. For example, food-based dietary compositions intended for use in humans, may include dairy products, grain product, etc. that are used separately or as a Supplement to other types of food, such as sauces, spices, powder, etc. with regard to diet compositions intended for use on such domestic animals such as dogs and/or cats, such compositions can be produced in the form of crackers or other attractive products, or as a complete and balanced food.

It should be noted that the shape of the diet composition, i.e. the type of the primary component or additive that will influence used in the composition, the amount of estrogen and/or androgen. According to a preferred variant embodiment of diet composition comprises, based on the total weight of the composition, of 0.001-10 wt.% estrogen and/or androgen, preferably 0.001 to 10 wt.% phytoestrogen and/or fitoestrogeni. More preferably, diet composition comprises, based on the total weight of the composition, from 0.01 to 10 wt.% estrogen and/or androgen, preferably, phytoestrogen and/or fitoestrogeni.

In the methods of the present invention, designed to reduce weight gain, usually occurring in a mammal due to sterilization, castration, spaying, oophorectomy is whether ovariohysterectomy, or in the postmenopausal period, diet composition used in mammals common or regularly, preferably daily. Consider diet composition includes food base and the component containing the estrogen, androgen, or their mixture in a quantity sufficient to reduce the weight gain that typically occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or in the postmenopausal period, and diet composition used in mammals, daily or on a regular basis. According to preferred variants of the considered methods component includes phytoestrogen, fitoestrogen or their mixture. In accordance with yet more preferred embodiments, the dietary composition is applied in a mammal in a quantity sufficient to provide in the body of a mammal estrogen, androgen, or a mixture thereof in a quantity of 0.001 to 100 mg per gram of the total diet of the mammal. More preferably, when the diet composition used in amounts sufficient to provide in the body of a mammal estrogen, androgen, or a mixture thereof in the amount of 1-2500 mg, and more preferably in the amount of 60-4000 μg per gram of the total diet of a mammal.

Such quantity e is trogen and/or androgen can be successfully ensure the application of the mammal products based on soy or products contains soy protein, for example a purified soy protein or soybean hypocotyl and/or products on the basis of flax seed or linseed protein, for example a purified linseed protein, e.g., in the amount of 1-50% of the total diet of a mammal, preferably in an amount of 1-35% by weight of the daily diet in the case when this method is aimed at reducing overweight people. The appropriate number of products based on soy or refined soya protein, or quantity of product from fermentation conversion of glycoside isoflavon in aglycone, comprise 1-1000 g of soy protein a day, and ways to reduce overweight people preferred are 5-500 g products based on soy or refined soya protein and/or products on the basis of Flaxseed or purified linseed protein a day. On the other hand, according to the technical solutions, in which the estrogen and/or androgen extracted from fungal, microbial or other natural or synthetic sources, the sources may be from 0.005 to 15 wt.% of the total diet of the mammal, and the amount of 0.005-10 wt.% are preferred for ways to reduce weight gain in humans. The appropriate amount of estrogen and/or androgen isolated from fungal, microbial or other natural sources, is predpochtitelno used in mammals in an amount of 0.1-100 mg of estrogen and/or androgen per kilogram of body weight of the mammal.

Diet composition can be applied in an amount to provide from 0.01 to 100 mg of estrogen, androgen, or a mixture thereof per kilogram body weight of the mammal, and in the case when the considered methods aimed at reducing overweight people, dogs, cats or horses, the most preferred amounts amount of 0.005-50 mg per kilogram body weight of the mammal. Such amount is preferably applied regularly or in any other way, preferably daily. To illustrate a specific embodiment variants of the invention, when the estrogen is daidzein, genistein or phytoestrogen similar patterns, diet composition is preferably applied at a mammal in a quantity sufficient to provide 0.1 to 80 mg daidzein and/or genistein per kilogram of body weight of the mammal, and the amount of 0.1-60 mg / kg, especially preferably for methods aimed at reducing overweight people. In that case, when estrogen is cholesterol or phytoestrogen similar patterns, diet composition used in the mammal in an amount sufficient to provide 0.5 to 50 mg phytoestrogen per kilogram of body weight of the mammal, and the amount of 0.1-30 mg per kilogram of body weight is preferred, if the IP is alzueta to reduce overweight people.

According to other variant embodiments, the dietary composition of the present invention include vitamins, minerals or their salts, dyes, preservatives and/or other additional components, which are traditionally used in mammals. Examples of suitable minerals may include calcium, phosphorus, potassium, sodium, iron, copper, zinc, manganese, iodine, selenium and the like, while suitable vitamins include vitamin a, various b vitamins, vitamin C, vitamin D and/or vitamin E. the Traditional diet of the feed additive may additionally include inulin, folic acid, Biotin, etc.

In accordance with a special variant embodiment of the invention, diet compositions include one or more calcium salts, one or more peptides and/or amino acid and/or derivative of tocopherol. The calcium salt is administered in the diet composition in an amount sufficient to ensure mammal 100-3000 mg of calcium salt per day, or 10-100 mg per kg of body weight of the mammal. Preferred peptide is a L-carnitine. Amino acids and/or di - and tripeptides preferably include in the diet composition in an amount of 0.1 to 400 ppm, or in an amount that is sufficient to provide 0.05 to 15 mg of amino acids per kilogram of body weight of the mammal per day. Proizvodi the e tocopherol, for example, alpha-tocopherol, or tocopherole mixture of natural origin can be used in an amount to provide 1-500 mg / day, or 1 to 10 mg per kilogram body weight of the mammal per day.

Information confirming the possibility of carrying out the invention

Compositions and methods of the present invention is additionally illustrated by the following examples. Unless otherwise noted, the Examples and in the text of this description, parts and percentages are given by weight.

Example 1

Were prepared diet compositions according to the present invention, comprising 0.001 to 200 mass parts of one or more derivatives phytoestrogen, 0.5 to 100 mass parts of L-carnitine, 0.1 to 500 mass parts of the calcium salt, from 0.5 to 60 mass parts of alpha-tocopherol or a mixture of Tocopherols, and 0.1 to 100 mass parts of the media, representing oligosaccharides, starch, protein, fat, and/or other fibrous or cellulosic components. Prepared other songs, which used 1-100 mass parts derivatives phytoestrogen and 1-100 mass parts derived androgen in combination with the specified quantities of L-carnitine, calcium salts, tocopherol and media. Such compositions are suitable for use in the methods of the present invention, designed to reduce weight gain usually occurs in the milk of tausaga due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy or postmenopausal period by a daily or other regular intake of 0.01-4000 grams or 0.01-50 wt.% of the total diet of a mammal.

Example 2

Were prepared diet composition in the form of a feed additive for dogs and cats containing ingredients in the amounts indicated in Table 1. In accordance with the methods of the present invention, feed additive for dogs used in an amount of about 10% of the total diet of the dog, for dogs weighing 35 kg is about 40 grams per day. Similarly, feed additive for cats used in an amount of about 10% of the total diet of cats in the amount of 5-10 grams per day. These feed additives used to reduce the weight gain that typically occurs in a mammal due to sterilization, castration, spaying, oophorectomy or ovariohysterectomy.

Table 1
Ingredients daily valueFeed additive for dogsFeed additive for cats
Daidzein, genistein or other phyto-estrogen (mg)100-4000(1500)20-400 (200)
Inulin (mg)5000500
CA (mg)2870570
P (mg)2150430
K (mg)2150290
Na(mg)800200
Fe(mg)166
Cu(mg)-4
Zn(mg)20,4
Mn (mg)30,4
I (mg)0,30,03
Se (mg)0,10,01
Vitamin a (IU)1000240
Vitamin D (IU)40050
Vitamin E (IU)5010
Thiamin (mg)51
Riboflavin (mg)21
Pantothenic acid (mg)155
Niacin (mg)155
Pyridoxine(mg)21
Folic acid (mg)0,10,05
Biotin (mg)0,20,1
Choline (mg)40050
Vitamin C (mg)52
Medium (mg)2000010000

Example 3

Were prepared diet composition in the form of treats for dogs and cats using the components and amounts listed in Table 2. Feed additive for dogs had a dog weighing 35 kg in the amount of about 4 g per day, whereas a feed additive for cats tested on the cat weighing 4 kg in the amount of about 2 g per day in accordance with the methods of the present invention.

Table 2
IngredientsFeed additive for dogsFeed additive for cats
Fish meal (mg)2000010000
Daidzein, genistein or other phyto-estrogen (mg)100-2000 (750)20-300 (150)
Flax flour (mg)1000500
Inulin (mg)1000100
Carnitine (mg)5015
CA (mg)400150
P (mg)350120
Fe (mg)52
Cu (mg)0,20,02
Zn (mg)2Mn (mg)30,4
Se (mg)0,010,001
Vitamin a (IU)400120
Vitamin D (IU)405
Vitamin E (IU)102
Thiamin (mg)10,1
Riboflavin (mg)0,20,1
Pantothenic acid (mg)1,50,5
Niacin(mg)1,50,5
Pyridoxine (mg)0,20,1
Folic acid (mg)0,010,005
Biotin (mg)0,020,01
Choline (mg)405,0
Vitamin C (mg)0,50,2
Arginine (mg)52
Methionine (mg)5025

Example 4

Were prepared diet composition in the form of liquid beverage and dry powder, respectively, using the components in amounts shown in Table 3. The resulting composition was tested on people to reduce excess weight, usually observed because UD is of the ovaries, oophorectomy or ovariohysterectomy or postclimacteric period, in the amount of 1-1000 ml / day, or 0.1 to 100 g per kilogram of body weight per day.

Table 3
IngredientsLiquid beverageDry powder
Skim milk88%-
Powdered skim milk-64%
Linen and/or soybean meal (47% protein)9,0%29,5%
The fructose oligosaccharide1,0%2,0%
Conjugated linoleic acid0,6%1,70%
Soybean oil0,45%a 1.75%
Vitamin mixture1,0%1,0%
Genistein, daidzein, and/or cholesterol or other estrogenic derivatives0,05%0,05%

The above examples and various preferred embodiments of the present invention is shown merely for purposes of illustration and in no way limit the scope of the invention defined by the claims. Other embodiments of the present invention and its advantages should be clear to the ordinary special is that in this area and are covered by the scope of the invention, defined in the following claims.

1. Diet composition intended for reducing weight normally encountered in domestic animals as a result of spaying, neutering, spaying, oophorectomy or ovariohysterectomy or postmenopausal period, while diet composition is a feed product for animals selected from the group consisting of a complete and balanced feed, treats and combinations thereof, and includes a base in the form of pet food component, including estrogen, androgen, or their mixture in a quantity sufficient to reduce the weight gain normally encountered in domestic animals as a result of spaying, neutering, spaying, oophorectomy or ovariohysterectomy or postmenopausal period with regular supply of pet this diet composition, and the estrogen or androgen is a phytoestrogen, fitoestrogen or their mixture, and the amount of phytoestrogen, fitoestrogeni or mixtures thereof is 0.001-10 wt.% based on the weight of the composition.

2. Diet composition according to claim 1, in which the phytoestrogen is an isoflavone, a lignin, coumestan, the lactone resorcinol acid or their mixture.

3. Diet composition according to claim 1, in which estrogen or androge is derived from soy and Flaxseed or their protein products.

4. Diet composition according to claim 1, in which the estrogen or androgen derived from fungal or microbial sources.

5. Diet composition according to claim 1, in which the basis in the form of pet food includes a food of animal origin, zernovyi product, starch, other cellulosic material or a mixture.

6. Diet composition according to claim 1, in which the phytoestrogen is daidzin, genshin, daidzein, genistein or cholesterol.

7. The way to reduce weight normally encountered in domestic animals as a result of spaying, neutering, spaying, oophorectomy or ovariohysterectomy or postmenopausal period, including regular introduction of domestic animal diet composition, representing a feed product for animals selected from the group consisting of a complete and balanced feed, treats and combinations thereof, and including a base in the form of pet food component, including estrogen, androgen, or their mixture in a quantity sufficient to reduce the weight gain normally encountered in domestic animals as a result of spaying, neutering, spaying, oophorectomy or ovariohysterectomy or postmenopausal period with regular supply of pet this diet composition, and ect is ogen or androgen is a phytoestrogen, fitoestrogen or their mixture and the amount of phytoestrogen, fitoestrogeni or mixtures thereof is 0.001-10 wt.% based on the weight of the composition.

8. The method according to claim 7, in which the estrogen is an isoflavone, a lignin, coumestan, the lactone resorcinol acid or their mixture.

9. The method according to claim 7, in which the estrogen is produced from soybean or linseed, or their protein products.

10. The method according to claim 7, in which the estrogen or androgen derived from fungal or microbial sources.

11. The method according to claim 7, in which the basis in the form of pet food includes a food of animal origin, grain product, starch, cellulose material or a mixture.

12. The method according to claim 7, in which the diet composition is used in an amount sufficient to provide animals with estrogen, androgen or mixtures thereof in an amount of from 0.001 to 100 mg per 1 g of the total diet of introduced domestic animal.

13. The method according to claim 7, in which the diet composition is used in an amount sufficient to provide animals with estrogen, androgen or mixtures thereof in an amount of from 1 mg up to 25,000 μg to 1 g, preferably from 60 to 4000 μg per 1 g of the total diet of introduced domestic animal.

14. The method according to claim 7, in which the diet composition is used in an amount sufficient to provide pet vetoes what Rogen, fitoestragenom or mixtures thereof in an amount of from 0.001 to 100 mg per 1 kg, preferably 0.005 to 50 mg per 1 kg of weight of a pet.

15. The method according to claim 7, in which the pet is a dog or a cat.



 

Same patents:

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of imidazole of the formula (I):

or its pharmaceutically acceptable salts wherein X represents -CH2-(CH2)p-, -O-; R1 represents phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (C3-C7)-cycloalkyl wherein indicated phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (C3-C7)-cycloalkyl are substituted optionally with 1-3 substitutes taken independently among halogen atom, -OH, halogen-(C1-C6)-alkyl, (C1-C6)-alkyl, (C1-C6)-alkoxy group and OH-(C1-C6)-alkyl; R2 represents hydrogen atom (H) or (C1-C6)-alkyl; R3 represents H or (C1-C6)-alkyl; R4 represents H or (C1-C6)-alkyl; R5 represents H, or R5 and R7 form in common a bond; each R6 represents independently halogen atom, -OH, halogen-(C1-C6)-alkyl, (C1-C6)-alkyl, (C1-C6)-alkoxy group or OH-(C1-C6)-alkyl; R7 represents H, or R7 and R5 form in common a bond; each R8 represents independently -OH, (C1-C6)-alkyl, halogen-(C1-C6)-alkyl or (C1-C6)-alkoxy group; m = 0, 1, 2 or 3; n = 0 or 1; p = 0 or 1; r = 0 or 1; t = 0. Also, invention relates to a method for preparing compounds of the formula (I) and to a pharmaceutical composition showing affinity to alpha-2-adrenoceptors based on these compounds. Invention provides preparing new compounds and pharmaceutical composition based on thereof used in aims for treatment of neurological disturbances, psychiatric disorders or disturbances in cognitive ability, diabetes mellitus, lipolytic diseases, orthostatic hypotension or sexual dysfunction.

EFFECT: improved preparing method, valuable medicinal properties of compounds and compositions.

25 cl, 1 tbl, 14 ex

Antagonist npy y5 // 2264810

FIELD: medicine, pharmacology.

SUBSTANCE: the present innovation deals with applying pharmaceutical composition as an antagonist of NPY Y5 receptor that contains the compound of formula I

, moreover, it deals with compounds of formula I and method for treating obesity and suppressing food intake, as well.

EFFECT: higher efficiency of therapy.

18 cl, 13 ex, 6 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to substituted 8,8a-dihydro-3aH-indeno[1,2-d]thiazoles and to their physiologically acceptable salts and physiologically functional derivatives also. Invention describes compounds of the formula (I): wherein R1 and R1' mean independently of one another H, F, Cl, Br, J; R2 and R3 means H; R4 means phenyl hat can be replaced with hydroxyl group (OH); R5 means hydrogen atom (H); R6 means OH. Also, invention describes a method for preparing these compounds. Compounds can be used as anorexic agents for prophylaxis and treatment of obesity.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

5 cl, 2 tbl, 1 ex

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to polycyclic dihydrothiazole and to their physiologically acceptable salts and physiologically functional derivatives. Invention describes compounds of the formula (I): wherein R1 and R1' mean independently of one another atoms of hydrogen (H), fluorine (F), chlorine (Cl), bromine (Br) and iodine (J); R2 and R3 mean hydrogen atom (H); R4 means (CH2)n-R5 wherein n can be = 0-6; R5 means phenyl that can be substituted with NH-SO2-(C1-C6)-alkyl, NH-SO2-phenyl being phenyl ring up to twice-fold can be substituted with chlorine atom (Cl), (CH2)m-SO2-NH2, (CH2)-SO2-NH-(C1-C6)-alkyl, (CH2)m-SO2-N-[(C1-C6)-alkyl]2 or (CH2)m-SO2-N-[=CH-N(CH3)2] wherein m can be = 0-6, and a method for their preparing. Compounds are useful, for example, as anorexic agents used in prophylaxis or treatment of obesity.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

5 cl, 12 tbl, 2 ex

FIELD: medicine, experimental medicine.

SUBSTANCE: one should introduce tripeptide Pro-Gly-Pro for laboratory animals as injections at the quantity of 0.09-1.0 mg/kg body weight, and, also, gelatin as fodder additive. The method suggested enables to suppress appetite, decrease the quantity of fodder intake that leads to decreased body weight as a result.

EFFECT: higher efficiency.

2 cl, 5 dwg, 5 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to polycyclic dihydrothiazoles and their physiologically acceptable salts and physiologically functional derivatives. Invention describes compounds of the formula (I): wherein r1 and R1' mean independently of one another atoms H, F, Cl, Br and J; R2 means hydrogen atom (H); R3 means chlorine (Cl), bromine (Br) atom; R4 means phenyl, and a method for their preparing. Compounds can be used, for example, as anorectics for prophylaxis or obesity treatment.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

5 cl, 2 tbl, 1 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a prophylactic or therapeutic agent used against hyperlipidemia and comprising as an active component the heterocyclic compound of the formula [1]:

or its pharmaceutically acceptable salt wherein R1 represents aryl optionally substituted with similar or different one-three groups taken among alkyl, halogenalkyl, trihalogen alkyl, alkoxy-group and halogen atom; Het represents bivalent aromatic heterocyclic group of the formula [5]:

wherein X represents oxygen, sulfur atom or NR6 wherein R6 represents hydrogen atom or alkyl; R2 represents hydrogen atom, alkyl or trihalogenalkyl; D represents alkylene and alkenylene; E represents group of the formulae [3] or [4] wherein Y represents oxygen or sulfur atom; R3 and R4 are similar or different and each represents hydrogen atom or alkyl; p = 1; Z represents carboxy-group, alkoxycarbonyl, cyano-group or 1H-5-tetrazolyl. Also, invention relates to new compounds belonging to group of above enumerated heterocyclic compounds of the formula [1] that show effect reducing blood triglycerides level, low density lipoprotein cholesterol, glucose and insulin or effect enhancing high density lipoprotein cholesterol and effect reducing the atherogenic effect. Therefore, these compounds can be used in prophylaxis or treatment of hyperlipidemia, arteriosclerosis, heart ischemic disease, brain infarction, rheocclusion after percutaneous intraluminal coronary angioplasty, diabetes mellitus and obesity.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

29 cl, 1 tbl, 170 ex

FIELD: endocrinology.

SUBSTANCE: abnormally corpulent persons are treated by reduced-caloricity diet with limited content of carbohydrate-containing components and fats. In particular, caloricity of meal is reduced to 1200 kcal, including carbohydrate-containing components with glycemic index below 40. When initial weight is reduced by 5% and the weight is stabilized for 3 months, caloricity is increased to a specified value, calculated in terms of formula for daily caloricity recommended by World Health Organization taking into account sex, age, weight, and physical activity, glycemic index of carbohydrate-containing components ranging from 40 to 69 until the weight is lowered to desired level.

EFFECT: achieved stable and long-term reduction of weight owing to lowered insulin resistance of organism.

3 tbl

FIELD: cosmetics, pharmaceutical chemistry.

SUBSTANCE: invention relates to cosmetic composition used for loss weight comprising at least one compound that induces producing IL-6 by adipocytes in form of mixture with NPY antagonist and/or α2 antagonist and with an excipient for the cosmetic variant. Invention provides effectiveness of fatty acids efflux from adipocytes and inhibitory effect on fatty acids incorporation into cells that results to the loss weight effect. The composition shows good stability in storage being without reducing its activity. The composition has no adverse effects.

EFFECT: valuable properties of composition.

11 cl, 3 dwg, 5 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of tetrahydroisoquinoline of the formula [I] wherein R1 represents hydrogen atom or lower alkyl; R2 represents alkyl having optionally a substitute taken among alkoxycarbonyl and carboxy-group, cycloalkyl, cycloalkylalkyl, aryl having optionally a substitute taken among lower alkyl, arylalkyl having optionally a substitute taken among lower alkyl, lower alkoxy-group, halogen atom and acyl, alkenyl, alkynyl, or monocyclic heterocyclylalkyl wherein indicated heterocycle comprises 5- or 6-membered ring comprising nitrogen atom and having optionally a substitute taken among lower alkyl; R3 represents hydrogen atom or lower alkoxy-group; A represents a direct bond or >N-R5 wherein R5 represents lower alkyl; B represents lower alkylene; Y represents aryl or monocyclic or condensed heterocyclyl comprising at least one heteroatom taken among oxygen atom and nitrogen atom and having optionally a substitute taken among lower alkyl, carboxy-group, aryl, alkenyl, cycloalkyl and thienyl, or to its pharmaceutically acceptable salt. Also, invention relates to pharmaceutical composition eliciting hypoglycaemic and hypolipidemic effect based on these derivatives. Invention provides preparing new compounds and pharmaceutical agents based on thereof, namely, hypoglycaemic agent, hypolipidemic agent, an agent enhancing resistance to insulin, therapeutic agent used for treatment of diabetes mellitus, therapeutic agent against diabetic complication, agent enhancing the tolerance to glucose, agent against atherosclerosis, agent against obesity, an anti-inflammatory agent, agent for prophylaxis and treatment of PPAR-mediated diseases and agent used for prophylaxis and treatment of X-syndrome.

EFFECT: valuable medicinal properties of compounds and composition.

13 cl, 7 tbl, 75 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with applying fulvestrant as a curative preparation of the third line in treating patients with resistant cancer of mammary gland after failed application of tamoxifen and aromatase inhibitor. The innovation shows positive therapeutic result in 41% cases.

EFFECT: higher sensitivity to fulvestrant.

5 cl, 1 ex, 1 tbl

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with applying fulvestrant as a curative preparation of the third line in treating patients with resistant cancer of mammary gland after failed application of tamoxifen and aromatase inhibitor. The innovation shows positive therapeutic result in 41% cases.

EFFECT: higher sensitivity to fulvestrant.

5 cl, 1 ex, 1 tbl

FIELD: medicine, dermatology.

SUBSTANCE: the present innovation deals with treating different forms of localized sclerodermia: plaque, linear, scleroatrophic lichen, idiopathic atrophodermia. The method deals with introducing delagyl, xanthinol nicotinate, claritine, application of "Elocom" ointment. At the background mentioned one should alternate 8-10 procedures of intravenous injection of ozonized physiological solution at ozone concentration being 1.5 mg/l at the volume of 200 ml and 5-7 procedures of subcutaneous puncturing in lesion foci with oxygen-ozone gaseous mixture at ozone concentration of 2 mg/l. This mixture should be introduced along focal periphery at the volume of 10-30 ml. Intravenous injections should be carried out twice or thrice weekly, and subcutaneous puncturing - once or twice weekly. The innovation enables to decrease sickness rate due to increased velocity and full-value absorption of the ointment used, immunomodulating, antiphlogistic, collagen-formation and microcirculation normalizing effect of complex therapy, liquidation of tissue hypoxia and reflexogenic stimulation of body vascular system.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: pharmaceutical composition possesses an anti-estrogenic effect. The composition comprises fulvestrant in ricinoleate vehicle, a pharmaceutically acceptable anhydrous ester solvent and pharmaceutically acceptable alcohol. The composition is adopted for intramuscular administration and maintains the therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks. The composition for intramuscular injection provides satisfied releasing fulvestrant for prolonged time.

EFFECT: valuable medicinal and pharmaceutical properties of composition.

32 cl, 4 tbl, 1 ex

FIELD: organic chemistry, steroids, medicine, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to an agent exhibiting structure 7β-hydroxyepiandrosterone or 7β-dehydroepiandrosterone, or their pharmaceutically acceptable esters of the structural formula (I) used for protection of neurons against their damages. Compounds elicit high effectiveness and bioavailability.

EFFECT: valuable medicinal properties of compounds.

15 cl, 3 dwg, 3 tbl, 22 ex

FIELD: organic chemistry, steroids, medicine, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to an agent exhibiting structure 7β-hydroxyepiandrosterone or 7β-dehydroepiandrosterone, or their pharmaceutically acceptable esters of the structural formula (I) used for protection of neurons against their damages. Compounds elicit high effectiveness and bioavailability.

EFFECT: valuable medicinal properties of compounds.

15 cl, 3 dwg, 3 tbl, 22 ex

FIELD: medicine, gynecology.

SUBSTANCE: invention relates to treatment of endometriosis and state associated with it. Method involves administration of LHRH antagonist by courses for 4-12 weeks. Also, method involves additional simultaneous and successive administration of nonsteroid anti-inflammatory agents, analgesic agents, contraceptive preparations and androgens. Invention provides prophylaxis of relapses of endometriosis symptoms in the absence of symptoms of estrogenic insufficiency.

EFFECT: improved and valuable method for treatment.

17 cl, 2 dwg

FIELD: organic chemistry, steroids, medicine, pharmacy.

SUBSTANCE: invention relates to steroid compounds of the formula (1)

wherein --- means optional double bonds; R6 means hydrogen atom (H), =CH, -CH3 or -CH2-CH3; R7 means hydrogen atom (H), (C1-C4)-alkyl, (C2-C5)-alkenyl, or (C2-C5)-alkynyl; R11 means hydrogen atom (H), (C1-C4)-alkyl, (C2-C4)-alkenyl, (C2-C4)-alkynyl, (C1-C4)-alkylidene; E means 5-7-memberd ring formed with 16 and 17 carbon atoms at α,cis-position relatively to steroid structure and comprising possibly up to two double bonds. Compounds can be used in therapy and in methods for selective modification of activity of estrogen receptors.

EFFECT: improved method for modifying, valuable medicinal properties of compounds.

10 cl, 1 sch, 1 tbl, 1 ex

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: invention relates to an antibacterial, anti-inflammatory, antiviral, antiherpetic agent used for treatment of vulvovaginitis, palanitis, ballanopostitis induced by microorganisms, candidas, viruses, chlamydia, trichomones and infections of herpes simplex virus and for treatment of acne also. Invention relates to an antibacterial, anti-inflammatory, antiviral, antiherpetic medicinal agent used for treatment of diseases transferred by sexual way, in particular, to vulvovaginitis, palanitis, ballanopostitis induced by microorganisms, candidas, viruses, chlamydia, trichomones and infections of herpes simplex virus and for treatment of acne. The medicinal agent comprises a mixture of cream-like base (vehicle) and an alcoholic extract from leaves, fruits and stems of plant Tribulus terrestris (active component). This active component comprises active substance from Tribulus terrestris with the high content of steroid saponins. Also, invention relates to a method for preparing an antibacterial, anti-inflammatory, antiviral, antiherpetic medicinal agent that involves analysis of parts of plant Tribulus terrestris for gathering and further extraction, namely to a sample of leaves, fruits and stems of plant Tribulus terrestris gathered in the definite time period. Method involves addition of deionized water, stirring and evaluation of the level of water and foam in a mixer. After proving readiness of plant Tribulus terrestris for gathering samples of leaves, fruits and stems of plant Tribulus terrestris are taken. Samples are dried, milled and deionized water is added. The prepared aqueous mixture is treated in mixer, the level of water and foam is evaluated in an aqueous mixture. The prepared mixture is remained for precipitation, filtered, ethyl alcohol is distilled off and the concentrated aqueous extract is prepared. The prepared active component is added to the cream base (vehicle) or to a base (suppository). Agent promotes to effective treatment of vulvovaginitis, palanitis, ballanopostitis induced by microorganisms, candidas, viruses, chlamydia, trichomones and infections of herpes simplex virus and to treatment of acne also.

EFFECT: valuable medicinal properties of agent.

5 cl, 5 dwg

FIELD: medicine, combustiology, surgery.

SUBSTANCE: one should apply monotherapy with ecdisterone solution in olive oil at concentration of 0.001-0.01% to be introduced per 10 ml thrice daily after meals for 10-14 d. The present innovation shortens terms of therapy in [patients with the above-mentioned nosology due to more rapid epithelization of esophageal mucosa.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: food industry.

SUBSTANCE: the suggested innovation deals with dietary products of functional indication necessary for sportsmen's nutrition. The product contains food vegetable phospholipids, taste-aromatic additives, ascorbic acid and grapes seed powder. As food vegetable phospholipids it contains a butter-fat phospholipid product obtained due to extracting phospholipid concentrates with ethanol at the ratio of phospholipid concentrates to ethanol being (1:3)-(1:7) at 40-60 C at developing alcohol-soluble and alcohol-insoluble fractions of phospholipids. Separation of alcohol-soluble fraction of phospholipids against alcohol-insoluble fraction of phospholipids and subsequent drying alcohol-insoluble fraction under vacuum at obtaining butter-fat phospholipid product has been, also, suggested. The powder out of grapes seeds has been obtained due to reducing at two stages, during the first stage grapes seeds should undergo fractioning followed by moisturizing up to 8-12% moisture content, and during the second stage - they should be finely reduced in a film of 0.1-0.2 mm thickness at 20-35 C. Moreover, all the ingredients applied should be taken at certain quantitative ratio. The suggested type of food functional product enables to create dietary product that is capable to quickly restore one's body after intensive muscular activity and increase body's ergogenic properties.

EFFECT: improved quality of the food product suggested.

2 ex, 3 tbl

Up!